Fritextsökning
Artiklar per år
Innehållstyper
-
Joy at Egetis after positive CHMP opinion – ”The single most important milestone”
Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."
-
Novo Nordisk to invest billions in new quality control lab
Novo Nordisk has announced plans to invest 2.9 billion Danish kroner in order to establish a new quality control laboratory in Hillerød in northern Zealand, Denmark.
-
Sobi announces agreement with Enable Injections
Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.
-
What will be the next big hype after obesity? – An expert panel highlighted their top picks
What will be the next big trend in life science? Everything from Alzheimer’s, Crispr and Omics were highlighted when the issue was debated at this year’s major life science event in Lund.
-
BioArctic moves forward with its candidate for Parkinson’s
BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.
-
Swedish pavilion with healthcare companies at Ukraine fair – “Ukraine is being rebuilt right now”
Private companies and public authorities are both needed in the reconstruction of Ukraine, said Minister for Health Care, Acko Ankarberg Johansson, in her opening speech in the Swedish pavilion at the ReBuild Ukraine fair.
-
Nobel Prize winner Torsten Wiesel turns 100: “Old men like me should use their experience to help the young”
In 1955, a young Torsten Wiesel jumped on a boat to the US and embarked on a fabulous career as a neuroscientist, crowned with a Nobel Prize for his work. Now 100 years old, he looks back on an intense life and his upbringing in Stockholm, Sweden, which shaped his desire to help the vulnerable in society.
-
Anna Törner: ”Me Tarzan, you Jane, nä det funkar inte längre!”
”Kanske det är dags att sluta att prata om manliga och kvinnliga egenskaper och istället referera till människor som handlingskraftiga, analyserande, inlyssnande och strategiska? Helt utan referens till kromosomuppsättning?”, skriver Anna Törner i en krönika.
-
Innovative start-up helps doctors, scientists and industry balance coagulation risks
For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thrombosis is an ongoing challenge. In the late 1980s, scientists at Maastricht University in the Netherlands developed an innovative method, the thrombin generation assay (TGA), which provides a complete overview of a physiological process crucial for maintaining normal haemostasis.
-
“Conducting research at universities is becoming more and more like working at a research hotel”
The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at Lund University, about research policy, the constant hunt for funding in academia and what constitutes ‘fine research’.
-
Han är ny på Sahlgrenska Science Park
Mats Hellström är Sahlgrenska Science Parks nya Lab Manager. I hans nya roll ska han se över satsningen Health Innovation Labs.
-
Study: Popular diabetes treatment is not associated with thyroid cancer
Concerns raised about an association between GLP-1 analogues, used to treat diabetes and obesity, and an increased risk of thyroid cancer are not supported by an extensive Scandinavian study.
-
Settlement of cancer allegations against blockbuster drug
French pharmaceutical company Sanofi has reached a principal agreement in the US on around 4,000 of the cases in which its now withdrawn blockbuster heartburn drug Zantac allegedly had caused cancer.
-
Ny vd för Boule Diagnostics
Diagnostikbolaget Boule Diagnostics har nu rekryterat en ny vd. Torben Nielsen efterträder Jesper Söderqvist som lämnar sin tjänst i mitten av april.
-
Marie Gårdmark: ”Interchangeable biological medicines – soon in a pharmacy near you?”
”Generic competition is an effective way to push down drug prices, but it has not worked equally well for biosimilars. Biosimilars require more time to gain market share compared to generics, and new biosimilars do not always lead to lower prices” writes Marie Gårdmark in a column.
-
To build trust, one must be able to say “I don’t know” – whether human or AI
Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.